MEDFAR Unveils New Brand Identity Reflecting Its Growth and Ambitious Healthcare Goals MONTREAL, Aug. 8, 2024 /PRNewswire/ - MEDFAR, developer...
The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globallySARASOTA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE)...
MIDDLETON, Wis., Aug. 7, 2024 /PRNewswire/ -- Natus Medical Incorporated has announced the launch of autoSCORE, the first-of-its-kind artificial intelligence...
CAMBRIDGE, Mass., Aug. 7, 2024 /PRNewswire/ -- LabCentral, the premier Massachusetts-based network of coworking labs designed to accelerate high-potential biotech startups, launched...
Silo to advance homing peptide development for initial indication in multiple sclerosis SARASOTA, FL, Aug. 07, 2024 (GLOBE NEWSWIRE) --...
BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical...
August 7, 2024News Release BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting COPENHAGEN, DENMARK and BOSTON, MA,...
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic...
Open label extension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024Selected by Food...
STOCKHOLM, SE / ACCESSWIRE / August 07, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a...
Revenue improved sequentially across all businessesCommercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially A record total...
Survey of C-Suite leaders highlights why life sciences commercial model requires an urgent shift SAN FRANCISCO, Aug. 6, 2024 /PRNewswire/...
Luminopia meets rigorous criteria set by Highmark's New Technology Advisory Committee (NTAC) and receives a positive coverage determination from the...
Figure 1 Combination of dulaglutide (Trulicity®) and buntanetap improves memory and synaptic plasticity in AD mice (*p<0.05, **p<0.01). Figure 2...
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025...
On track to report preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in Q4 2024...
WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program...
Initial Phase 2 data of BDTX-1535 in 2L/3L patients with EGFRm NSCLC on track for later in Q3 2024On track...
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Anavex...
Generated Robust 28% Year-over-Year Revenue Growth in Q2 2024 Recorded Positive Quarterly Net Income for Third Consecutive Quarter, and Positive...